Tianjin Pharmaceutical Da Ren Tang's (SGX:T14, SHA:600329) net profit attributable to owners of the parent declined 3% during the first quarter of the year to 374.2 million yuan from 387.3 million yuan a year earlier, according to a filing with the Singapore Exchange on Tuesday.
Earnings per share dropped to 0.49 yuan compared with 0.50 yuan in the comparable period.
Revenue declined 30% year over year to 1.46 billion yuan from 2.09 billion yuan, due to a change in the consolidation scope which excluded data from Tianjin Zhongxin Medicine.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。